Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

1mmol/ml - sodium bicarbonate - solution for injection - 84mg/1ml

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - calcium pantothenate -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide sodium, quantity: 10.664 mg/ml (equivalent: furosemide, qty 10 mg/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide - oedema: lasix is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. lasix is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. lasix injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, lasix is indicated by the intravenous route. parenteral use should be replaced with oral lasix as soon as practical.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - gentamicin sulfate 10 mg/ml (gentamicin sulfate 16mg/ml (bp) equivalent to 10mg/ml (10,000iu) gentamicin) - solution for infusion - 10 mg/ml - active: gentamicin sulfate 10 mg/ml (gentamicin sulfate 16mg/ml (bp) equivalent to 10mg/ml (10,000iu) gentamicin) excipient: disodium edetate dihydrate sodium hydroxide sulfuric acid water for injection - dbl™ gentamicin injection bp is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: pseudomonas aeruginosa proteus species (indole positive and indole negative) escherichia coli klebsiella - enterobacter - serratia species staphylococcus species (coagulase positive and coagulase negative) dbl™ gentamicin injection bp should be considered for the treatment of the following conditions when caused by susceptible organisms: septicaemia respiratory tract infections infected wounds, bone and soft tissue infections including peritonitis, septic abortion and burns complicated by sepsis urinary tract infections (recurrent, complicated) dbl™ gentamicin injection bp is not routinely indicated in the initial treatment of uncomplicated urinary tract infections unless the organism is resistant to other less toxic antibacterials. dbl™ gentamicin injection bp may be considered as initial therapy in suspected or confirmed gram negative infections and therapy may be instituted before obtained results of susceptibility testing. if anaerobic organisms are suspected, additional antimicrobial therapy should be added to the gentamicin regime.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - gentamicin sulfate 65mg (gentamicin sulfate 65 mg/ml (bp) equivalent to 40mg/ml (40,000iu) gentamicin); gentamicin sulfate 65mg (gentamicin sulfate 65 mg/ml (bp) equivalent to 40mg/ml (40,000iu) gentamicin) - solution for injection - 40 mg/ml - active: gentamicin sulfate 65mg (gentamicin sulfate 65 mg/ml (bp) equivalent to 40mg/ml (40,000iu) gentamicin) excipient: disodium edetate dihydrate sodium hydroxide sulfuric acid water for injection active: gentamicin sulfate 65mg (gentamicin sulfate 65 mg/ml (bp) equivalent to 40mg/ml (40,000iu) gentamicin) excipient: disodium edetate dihydrate sodium methyl hydroxybenzoate sodium propyl hydroxybenzoate water for injection - dbl™ gentamicin injection bp is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: pseudomonas aeruginosa proteus species (indole positive and indole negative) escherichia coli klebsiella - enterobacter - serratia species staphylococcus species (coagulase positive and coagulase negative) dbl™ gentamicin injection bp should be considered for the treatment of the following conditions when caused by susceptible organisms: septicaemia respiratory tract infections infected wounds, bone and soft tissue infections including peritonitis, septic abortion and burns complicated by sepsis urinary tract infections (recurrent, complicated) dbl™ gentamicin injection bp is not routinely indicated in the initial treatment of uncomplicated urinary tract infections unless the organism is resistant to other less toxic antibacterials. dbl™ gentamicin injection bp may be considered as initial therapy in suspected or confirmed gram negative infections and therapy may be instituted before obtained results of susceptibility testing. if anaerobic organisms are suspected, additional antimicrobial therapy should be added to the gentamicin regime.

Malta - engelsk - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - cefazolin sodium - powder for solution for injection/infusion - cefazolin sodium 1 g - antibacterials for systemic use

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - dalteparin sodium - solution for injection - 10000unit/1ml

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - white shrimp -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - secale cereale -

Irland - engelsk - HPRA (Health Products Regulatory Authority)

amdipharm limited - gentamicin sulfate - solution for injection - 80 mg/2ml - other aminoglycosides; gentamicin